Effect of biotin supplementation on the vLa4 of thoroughbred horses

Thoroughbred horses in racing condition were supplemented twice daily with 25 mg biotin (biotin group), while control horses received an equivalent amount of maltodextrose as a placebo (placebo group). Changes of v_fLa4 (running speed necessary for producing a lactate concentration of 4 mmol/l in the blood) were determined with an incremental step test within three days and after two, three and four months after the beginning of supplementation. The mean v_fLa4 of both the biotin and the placebo groups (5 horses each) did not change significantly within three days of supplementation, but the mean plasma biotin concentration increased in the biotin group from 1.3±0.4 to 47±22 nmol/l (p<0.01), while remaining below 3 nmol/1 in the placebo group. There was no significantly different development of the v_fLa4 between groups over four months of supplementation. But, while the mean v_fLa4 of Thoroughbreds supplemented with biotin over this period of time did not show any changes, the v_fLa4 of the placebo group horses showed a tendency to decrease. In the biotin group, the mean plasma biotin levels varied between 38 and 64 nmol/l over the four months, while the biotin concentration of the placebo group never exceeded 3 nmol/1.     

In Vitro and In Vivo Evaluation of Ferric-Hyaluronate Implants for Delivery of Amikacin Sulfate to the Tarsocrural Joint of Horses

Objective— To assess the antimicrobial elution characteristics, toxicity, and antimicrobial activity of amikacin‐impregnated ferric‐hyaluronate implants (AI‐FeHAI) for amikacin delivery to the tarsocrural joint of horses. Study Design— Experimental study. Sample Population— AI‐FeHAI implants, equine cartilage, and synovium, and horses (n=6). Methods— In vitro study: Five AI‐FeHAI were placed in saline solution with daily replacement until implant degradation. Eluent was tested for amikacin concentration and bioactivity. Synovial and cartilage explants were incubated in the presence or absence of AI‐FeHAI for 72 hours and subsequently assessed for morphology, viability, and composition. Synovial explants were incubated with Staphylococcus aureus in the presence or absence of AI‐FeHAI. Spent medium was cultured daily and explants were assessed for morphology and viability after 96 hours. In vivo study: AI‐FeHAI were placed in 6 tarsocrural joints. Standard cytologic analysis and amikacin concentration (SFAC) were determined in synovia obtained regularly for 28 days thereafter. Similar analyses were conducted after a single intra‐articular injection of amikacin 6 months later. Results— In vitro study: Amikacin concentrations exceeded 16 μg/mL and inhibited S. aureus growth for 8 days. AI‐FeHAI had no effect on cartilage explants. AI‐FeHAI eliminated bacteria from synovial explants. In vitro study: After AI‐FeHAI placement, SFAC was highest (140.78+63.81 μg/mL) at first sampling time. By 24 hours SFAC was <16 μg/mL. After intra‐articular injection, SFAC was the highest (377.91 ± 40.15 μg/mL) at first sampling time. By 48 hours SFAC was <16 μg/mL. Conclusions— A single intra‐articular amikacin injection demonstrated superior pharmacokinetics than AI‐FeHAI prepared as described. Clinical Relevance— AI‐FeHAI cannot be recommended for clinical use.     

A comparison of subarachnoid buprenorphine or xylazine as an adjunct to lidocaine for analgesia in goats

ObjectiveTo test the hypothesis that subarachnoid administration of buprenorphine and lidocaine provides more intense and longer lasting perioperative analgesia with less side effects than xylazine and lidocaine in goats.Study designRandomized, blinded, controlled study.Study animals Ten healthy female goats randomly assigned to two groups of five animals each.MethodsAfter sedation with acepromazine (0.1 mg kg^?1) intravenously (IV), lidocaine 2% (0.1 mL kg^?1) combined with either xylazine (0.05 mg kg^?1; Group X) or buprenorphine (0.005 mg kg^?1; Group B) were injected intrathecally at the lumbo-sacral junction prior to stifle surgery. Electrocardiogram, heart rate, direct systolic, mean, and diastolic arterial blood pressures, rectal temperature and arterial blood gases were recorded as were post-operative sedation and pain scores using a visual analogue and numeric rating scale, respectively. Data were analyzed with one-way anova for repeated measures, one-way anova, Friedman's and Kruskal–Wallis tests as necessary (p< 0.05).ResultsSurgery was successfully performed under both analgesia protocols. Total pain and sedation scores were significantly lower in the B as compared with X group from 3–24 hours and 30–120 minutes, respectively after subarachnoid drug administration (SDA). Heart rate and arterial blood pressures decreased post SDA and were consistently lower in X versus B (p< 0.05). In B arterial blood gas parameters did not change post SDA, but in group X PaCO₂ increased slightly within 15 minutes of SDA and remained elevated for at least 3 hours (p< 0.05).ConclusionIn these goats intrathecal administration of buprenorphine and lidocaine produced more profound and longer lasting analgesia with less sedation and hemodynamic and respiratory impairment than xylazine with lidocaine.Clinical relevanceIn these goats undergoing hind limb surgery, subarachnoid buprenorphine/lidocaine offered more intense and longer lasting analgesia than a xylazine/lidocaine combination, with less sedation and impairment of cardiopulmonary function.     

ULTRASONOGRAPHIC FINDINGS IN CANINE GASTRIC NEOPLASIA IN 13 PATIENTS

The ultrasonographic findings in 13 canine patients with histopathologically proven gastric tumors were reviewed. The echogenicity of gastric wall lesions was variable and independent of the type of tumor. All dogs had an increase in gastric wall thickness and in only one dog was the wall layering intact. Regional lymph node involvement was a common finding, but abnormalities within the liver were seen in only one patient. Gastric neoplasia was observed most commonly in middle-aged and old, medium- to large-sized dogs. Carcinoma was the most common tumor found. In this study, with a limited number of animals and limited tumor types, it appeared that thickening of the gastric wall, accompanied by loss of gastric wall layering and enlargement of regional lymph nodes were ultrasonographic signs likely to be found with gastric neoplasia. In this limited study the histologic type of gastric tumor could not be predicted on the basis of the ultrasound examination.     

The high incidence of coronary heart disease in Finland and its probable causes

The mortality from coronary heart disease (CHD) in Finland is remarkably high; according to the vital statistics released by the World Health Organization it has for many years been the highest in the world. This, however, concerns only the male sex; in the females the mortality figures, though also relatively high, do not very markedly differ from those of many other populations. It is also noteworthy that the CHD mortality in the eastern provinces of Finland is higher than in the western provinces. In the etiology of CHD a number of risk factors have been identified. The major ones are: high serum cholesterol values, cigarette smoking, and hypertension. The presence of two or more factors greatly increases the risk. In Finland the serum cholesterol determinations have generally revealed mean values which in comparison with similar populations from other countries are remarkably high. Mean values of the magnitude of some 260 to 280 mg per 100 ml have been reported for certain population groups. These high serum cholesterol values are probably chiefly dependent on the diet. The dietary intake of saturated fats (S) is very high and that of polyunsaturated fats (P) is low. The dietary P/S ratio is exceptionally low. It may also be possible that the population of Finland is genetically unusually susceptible to hyperlipidemia and hence also to CHD. However, the evidence to support such a view is meager. Cigarette smoking, a further important risk factor, is quite common in the country, and the mean consumption of cigarettes is relatively high. Hypertension also is prevalent in Finland. This may, at least partly, be due to the very high dietary intake of salt. Thus a number of generally recognized risk factors for CHD occur in Finland in a markedly high degree. Whether they can wholly explain the unusually high mortality from CHD or whether additional yet unrecognized risk factors are also involved, is difficult to decide.